Primary superficial small cell neuroendocrine carcinoma of esophagus: clinicopathologic and immunohistochemical analysis of 15 cases.
- Author:
Jun LU
1
;
Ning LÜ
;
Li-yan XUE
;
Shuang-mei ZOU
;
Xiu-yun LIU
;
Peng WEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antiporters; metabolism; CD56 Antigen; metabolism; Carcinoma, Neuroendocrine; metabolism; pathology; Carcinoma, Small Cell; metabolism; pathology; Chemoradiotherapy, Adjuvant; Chromogranin A; metabolism; Esophageal Neoplasms; metabolism; pathology; surgery; Esophagectomy; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Nuclear Proteins; Phosphopyruvate Hydratase; metabolism; Retrospective Studies; Survival Rate; Synaptophysin; metabolism; Thyroid Nuclear Factor 1; Transcription Factors
- From: Chinese Journal of Pathology 2011;40(11):736-740
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinicopathologic and immunohistochemical features of primary superficial esophageal small cell neuroendocrine carcinoma (ESCNC).
METHODSThe clinical, pathologic and immunohistochemical features were retrospectively analyzed in 15 cases of superficial ESCNC. An immunohistochemical study for chromogranin A, neuron-specific enolase, synaptophysin, CD56, TTF-1, 34βE12, AE1/AE3, and CK10/13 was performed.
RESULTSSuperficial ESCNC accounted for 4.8%(15/312) of all cases of superficial carcinoma of the esophagus encountered during the same period. The median survival time was 19 months and the mean survival time was 23.7 months after diagnosis. The one, two and five-year survival rates were 10/15, 5/15 and 1/15, respectively. The immunophenotypic profile was as follows: neuron-specific enolase (15/15), synaptophysin (15/15), AE1/AE3 (15/15), CD56 (14/15), TTF-1 (9/15), chromogranin A (8/15), 34βE12 (1/15) and CK10/13 (0/15).
CONCLUSIONSSuperficial ESCNC is a rare and aggressive malignant tumor with poor prognosis. Surgical resection coupled with post-operative chemoradiotherapy is the mainstay of treatment. The immunohistochemical study is valuable in pathologic diagnosis and differential diagnosis.
